Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Covid-19 (회복)로 병원에 입원 한 환자의 콜히친 : 무작위, 통제, 오픈 라벨, 플랫폼 시험
Randomized Controlled Trial
[키워드] (Medical Research Council)
1:1
28-day mortality
allocation concealment
Analysis
anti-inflammatory actions
assigned
baseline
both groups
by mouth
clinically suspected
clinician
Colchicine
colchicine 1 mg
colchicine group
composite endpoint
CYP3A4
CYP3A4 inhibitor
death
died
Diltiazem
discharge
discharged
Efficacy and safety
eligible
enrolled
estimated glomerular filtration rate
evaluate
filtration rate
finding
followed by
for inclusion
Frequency
funding
glomerular filtration rate
had no
hospital
Hospital stay
hospitalised
hospitals in Indonesia
hospitals in Nepal
in both groups
Indonesia
Innovation
Intention
intention-to-treat
Invasive mechanical ventilation
ISRCTN
Laboratory
less
medical history
Medical Research Council
moderate
nasogastric tube
Nepal
no significant difference
Open-label
open-label trial
opinion
participant
Patient
Platform trial
Primary outcome
proportion
randomisation
randomised
Randomly
rate ratio
receive
receiving
RECOVERY trial
reductions
reductions in
Registered
risk
risk ratio
SARS-COV-2 infection
secondary endpoint
Secondary endpoints
significant difference
Standard of care
subgroups of patients
the patient
Treatment
treatment for COVID-19
Trial
twice a day
usual care
usual care group
web-based simple
Wellcome Trust
with COVID-19
[DOI] 10.1016/S2213-2600(21)00435-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/S2213-2600(21)00435-5 PMC 바로가기 [Article Type] Randomized Controlled Trial